Conjugated Estrogens Vaginal Cream (US)

SECTION 2: Hazards identification

Appearance White Cream

Hazard statements

Non-hazardous in accordance with international standards for workplace safety.

Additional information

Short Term May cause eye and skin irritation (based on components) Long Term Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea). Known Clinical Effects Clinical use of this drug has caused menstrual irregularities, lack of menstrual periods (amenorrhea), changes in cervical erosion and secretion, breast enlargement, breast pain, breast development in males (gynecomastia), nausea, vomiting, abdominal cramping, weight changes, fluid retention, changes in sexual desire (libido), loss of hair, mental depression. EU Classification EU Indication of danger Not classified Australian Hazard Classification (NOHSC) Non-Hazardous Substance. Non-Dangerous Goods. Note This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

2.1 Classification of the substance or mixture

EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC)